FDA’s ‘Monster’ Proposed Rule Targets Patent Use Codes, Paragraph IV Certification
This article was originally published in The Pink Sheet Daily
Executive Summary
Industry has 90 days to comment on FDA’s current handling of generic challenges to brand protections.
You may also be interested in...
Patent Regulation Drops Deference To ANDA, 505(b)(2) Sponsors
FDA's final rule implementing provisions of Medicare Modernization Act ‘will fuel litigation,’ attorney predicts.
ANDA Changes May Require Paragraph IV Recertification, New 30-Month Stay
Brand litigants are beginning to argue that post-Markman application tweaks are in essence new applications eligible for new 30-month stays.
Patent Use Codes For Brands Can Be Challenged By Generics, Supreme Court Rules
The high court says the Hatch-Waxman Act did not intend for one patented use of a drug to prevent the marketing of a generic for unpatented uses; Justice Sotomayor criticizes FDA for not providing clearer direction to brand manufacturers about what to include in their use codes.